Although EGFR inhibitors have not been shown to significantly upregulate Wnt signaling in preclinical investigations, Wnt/β-catenin signaling promotes resistance to EGFR inhibitors in EGFR-mutated LC cells. The gene discussed is EGFR; the disease is laryngotracheoesophageal cleft.